Comprehensive analysis identifies novel targets of gemcitabine to improve chemotherapy treatment strategies for colorectal cancer

Gemcitabine (GEM) is a second-line anticancer drug of choice for some colorectal cancer (CRC) patients, and GEM inability to be commonly available in the clinic due to the lack of clarity of the exact action targets.The half maximal inhibitory concentration (IC50) of GEM treatment for 42 CRC cell lines were accessed from the Genomics of Drug sensitivity in Cancer (GDSC) database. High-throughput sequencing data of CRC patients were captured in The Cancer Genome Atlas (TCGA) and Weighted correlation network analysis (WGCNA) was conducted. Pearson correlations were derived for GEM potency-related genes. Differential analysis was conducted in the TCGA cohort to obtain CRC development-related genes (CDRGs), and univariate COX model analysis was performed on CDRGs overlapping with GEM potency-related genes to obtain CDRGs affecting CRC prognosis. Hub genes affecting GEM potency were identified by Spearman correlation.CALB2 and GPX3 were identified as potential targets for GEM treatment of CRC via prognostic analysis, which we also observed to be elevated with elevated clinical stage in CRC patients. The enhanced expression of CALB2 and GPX3 genes identified in the pathway analysis might inhibit the body metabolism as well as activate immune and inflammation related pathways. In addition, we found that CALB2 and GPX3 could also be considered as prognostic biomarkers in pan-cancer. Finally, we found that CALB2 and GPX3 were remarkably associated with the drug sensitivity of MG-132, Dasatinib, Shikonin, Midostaurin, MS-275, and Z-LNle-CHO, which were expected to be the drugs of choice for GEM combination.CALB2 and GPX3 represent prognostic biomarkers for CRC and they might be potential action targets for GEM. Our study offered innovative ideas for GEM administration strategies.

[1]  H. Kovacic,et al.  Gemcitabine: An Alternative Treatment for Oxaliplatin-Resistant Colorectal Cancer , 2022, Cancers.

[2]  Tonglian Wang,et al.  Sangerbox: A comprehensive, interaction‐friendly clinical bioinformatics analysis platform , 2022, iMeta.

[3]  F. Meng,et al.  CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy. , 2022, Acta biomaterialia.

[4]  M. Royzen,et al.  Recent Development of Prodrugs of Gemcitabine , 2022, Genes.

[5]  Chunyang Jiang,et al.  Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms , 2021, Molecular Cancer.

[6]  Yutian Li,et al.  Suppression of CD13 Enhances the Cytotoxic Effect of Chemotherapeutic Drugs in Hepatocellular Carcinoma Cells , 2021, Frontiers in Pharmacology.

[7]  D. Schrag,et al.  Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. , 2021, JAMA.

[8]  G. Bergers,et al.  The metabolism of cancer cells during metastasis , 2021, Nature Reviews Cancer.

[9]  Jun Yu,et al.  Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications , 2020, Oncogene.

[10]  X. Mao,et al.  An Eight-CircRNA Assessment Model for Predicting Biochemical Recurrence in Prostate Cancer , 2020, Frontiers in Cell and Developmental Biology.

[11]  F. Finkernagel,et al.  Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion , 2020, Molecular oncology.

[12]  E. Rennert-May,et al.  Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  A. Bardelli,et al.  Adaptive mutability of colorectal cancers in response to targeted therapies , 2019, Science.

[14]  K. Brandt,et al.  Soil bacteria and protists show different sensitivity to polycyclic aromatic hydrocarbons at controlled chemical activity. , 2019, FEMS microbiology letters.

[15]  R. Drmanac,et al.  Impact of sequencing depth and technology on de novo RNA-Seq assembly , 2019, BMC genomics.

[16]  Raju C Reddy,et al.  Role of GPx3 in PPAR&ggr;‐induced protection against COPD‐associated oxidative stress , 2018, Free radical biology & medicine.

[17]  Adrian V. Lee,et al.  An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics , 2018, Cell.

[18]  T. Cotter,et al.  ROS signalling in the biology of cancer. , 2017, Seminars in cell & developmental biology.

[19]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[20]  J. H. Kim.  Chemotherapy for colorectal cancer in the elderly. , 2015, World journal of gastroenterology.

[21]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[22]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[23]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[24]  Caitlyn W. Barrett,et al.  Tumor suppressor function of the plasma glutathione peroxidase gpx3 in colitis-associated carcinoma. , 2013, Cancer research.

[25]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[26]  P. Johnston,et al.  Calbindin 2 (CALB2) Regulates 5-Fluorouracil Sensitivity in Colorectal Cancer by Modulating the Intrinsic Apoptotic Pathway , 2011, PloS one.

[27]  J L Sebaugh,et al.  Guidelines for accurate EC50/IC50 estimation , 2011, Pharmaceutical statistics.

[28]  Ben S. Wittner,et al.  Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1 , 2009, Nature.

[29]  J. Loscalzo,et al.  Regulation of the extracellular antioxidant selenoprotein plasma glutathione peroxidase (GPx-3) in mammalian cells , 2009, Molecular and Cellular Biochemistry.

[30]  S. Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[31]  K. Park,et al.  Glutathione Peroxidase 3 Mediates the Antioxidant Effect of Peroxisome Proliferator-Activated Receptor γ in Human Skeletal Muscle Cells , 2008, Molecular and Cellular Biology.

[32]  C. Genton,et al.  Selective distribution of calretinin in adenocarcinomas of the human colon and adjacent tissues. , 1999, The American journal of surgical pathology.

[33]  C. Genton,et al.  Selective immunocytochemical localisation of calretinin in the human ovary , 1997, Histochemistry and Cell Biology.

[34]  J. Cox,et al.  Comparison of the Ca2+-binding Properties of Human Recombinant Calretinin-22k and Calretinin* , 1997, The Journal of Biological Chemistry.

[35]  B. Schwaller,et al.  Heterogeneity of expression of the calcium-binding protein calretinin in human colonic cancer cell lines. , 1996, Anticancer research.

[36]  G. Viale,et al.  Calretinin: a novel immunocytochemical marker for mesothelioma. , 1996, The American journal of surgical pathology.

[37]  Heyi Miao,et al.  Small Molecular Gemcitabine Prodrugs for Cancer Therapy. , 2019, Current medicinal chemistry.

[38]  Ash A. Alizadeh,et al.  Profiling Tumor Infiltrating Immune Cells with CIBERSORT. , 2018, Methods in molecular biology.

[39]  L. Litzky,et al.  Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma , 2005, Modern Pathology.